Comments on: Hassan Comes Clean About Vytorin. Or Did He? http://www.pharmalot.com/2008/02/hassan-comes-clean-about-vytorin-or-did-he/ News, Comment and Conversation Fri, 10 Feb 2012 20:20:18 +0000 http://wordpress.org/?v=2.6.2 By: Aubrey http://www.pharmalot.com/2008/02/hassan-comes-clean-about-vytorin-or-did-he/#comment-170333 Aubrey Thu, 21 Feb 2008 01:39:18 +0000 http://www.pharmalot.com/2008/02/hassan-comes-clean-about-vytorin-or-did-he/#comment-170333 The mystery solved <a href="http://scientific-misconduct.blogspot.com/2008/02/enhance-trial-mystery-solved-ceo-sees.html" rel="nofollow">Schering CEO saw outcome in piece of toast</a> Aubrey The mystery solved

Schering CEO saw outcome in piece of toast

Aubrey

]]> By: BDM http://www.pharmalot.com/2008/02/hassan-comes-clean-about-vytorin-or-did-he/#comment-168206 BDM Tue, 19 Feb 2008 17:35:08 +0000 http://www.pharmalot.com/2008/02/hassan-comes-clean-about-vytorin-or-did-he/#comment-168206 Fred Hassan was certainly quite cautious with his comments during the interview. The only way that the truth will be known is by a full investigation. A very interesting article about the ENHANCE study appeared in the New Jersey Star Ledger on Sunday, February 17, regarding who knew what when at Schering-Plough: "The most troubling shortcoming, the experts said, came when Schering-Plough's statisticians reviewed some raw study data in April 2006 before the examinations of all 750 volunteer test subjects at 11 sites around the globe were complete. Critics protest the statisticians may have had a hint of the study's disappointing outcome. "That is the key irregularity," said Eric Topol, a respected cardiologist and director of the Scripps Translational Science Institute, in La Jolla, Calif., who criticized the study's "poor organization, poor planning." "Maybe everything is on the up and up," he said, "but the right questions need to be answered." Merck and Schering-Plough said the numbers crunchers only saw partial data and could not draw conclusions about the study's final results." Is this the final word? One has to wonder! Fred Hassan was certainly quite cautious with his comments during the interview. The only way that the truth will be known is by a full investigation. A very interesting article about the ENHANCE study appeared in the New Jersey Star Ledger on Sunday, February 17, regarding who knew what when at Schering-Plough:

“The most troubling shortcoming, the experts said, came when Schering-Plough’s statisticians reviewed some raw study data in April 2006 before the examinations of all 750 volunteer test subjects at 11 sites around the globe were complete.

Critics protest the statisticians may have had a hint of the study’s disappointing outcome.

“That is the key irregularity,” said Eric Topol, a respected cardiologist and director of the Scripps Translational Science Institute, in La Jolla, Calif., who criticized the study’s “poor organization, poor planning.”

“Maybe everything is on the up and up,” he said, “but the right questions need to be answered.”

Merck and Schering-Plough said the numbers crunchers only saw partial data and could not draw conclusions about the study’s final results.”

Is this the final word? One has to wonder!

]]> By: Anon http://www.pharmalot.com/2008/02/hassan-comes-clean-about-vytorin-or-did-he/#comment-167859 Anon Tue, 19 Feb 2008 13:50:08 +0000 http://www.pharmalot.com/2008/02/hassan-comes-clean-about-vytorin-or-did-he/#comment-167859 He had every opportunity, but wouldn't do it. This looks bad, very bad. The major problem is that it will be the employees and the shareholders who will feel the eventual pain. He had every opportunity, but wouldn’t do it. This looks bad, very bad. The major problem is that it will be the employees and the shareholders who will feel the eventual pain.

]]> By: Booya http://www.pharmalot.com/2008/02/hassan-comes-clean-about-vytorin-or-did-he/#comment-166115 Booya Mon, 18 Feb 2008 19:30:48 +0000 http://www.pharmalot.com/2008/02/hassan-comes-clean-about-vytorin-or-did-he/#comment-166115 As alredy noted, Cramer gave him a bull, which seemed appropriate. Also it was noted that SP is the only pharm co. that Cramer has in his 'charitable trust.' Which widens the meanings of both "charitable" and "trust." As alredy noted, Cramer gave him a bull, which seemed appropriate.

Also it was noted that SP is the only pharm co. that Cramer has in his ‘charitable trust.’

Which widens the meanings of both “charitable” and “trust.”

]]> By: www.worldpharmanews.net http://www.pharmalot.com/2008/02/hassan-comes-clean-about-vytorin-or-did-he/#comment-163871 www.worldpharmanews.net Sun, 17 Feb 2008 16:57:08 +0000 http://www.pharmalot.com/2008/02/hassan-comes-clean-about-vytorin-or-did-he/#comment-163871 <strong>Pharmalot » Hassan Comes Clean About Vytorin. Or Did He?...</strong> A few day ago, Schering-Plough ceo Fred Hassan appeared on CNBC's Mad Money, where he spoke with Jim Cramer, the hyperactive host, about the controversy surrounding Vytorin. In particular, Cramer asked questions about the famous Enhance trial, which f... Pharmalot » Hassan Comes Clean About Vytorin. Or Did He?…

A few day ago, Schering-Plough ceo Fred Hassan appeared on CNBC’s Mad Money, where he spoke with Jim Cramer, the hyperactive host, about the controversy surrounding Vytorin. In particular, Cramer asked questions about the famous Enhance trial, which f…

]]> By: Matt http://www.pharmalot.com/2008/02/hassan-comes-clean-about-vytorin-or-did-he/#comment-162855 Matt Sun, 17 Feb 2008 06:16:54 +0000 http://www.pharmalot.com/2008/02/hassan-comes-clean-about-vytorin-or-did-he/#comment-162855 Right... I believe him as much as I would any politician or a#@@#@1 who is just plain coverring his own @#@... Big Pharma sucks. Right… I believe him as much as I would any politician or a#@@#@1 who is just plain coverring his own @#@…

Big Pharma sucks.

]]>